Improved hemocompatibility of polysulfone hemodialyzers with Endexo® surface modifying molecules
- 24 December 2021
- journal article
- research article
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 110 (6), 1335-1343
- https://doi.org/10.1002/jbm.b.35003
Abstract
Anticoagulation therapy is widely used to reduce clotting during hemodialysis (HD), but may cause adverse effects in end-stage kidney disease patients. A new hemodialyzer with a membrane modified by surface modifying molecule was developed to improve hemocompatibility that aimed to reduce the need for anticoagulation during dialysis treatments. We compared membrane surface characteristics and in vitro hemocompatibility of the new hemodialyzer to the standard polysulfone (PSF) hemodialyzer membrane. Scanning electron microscopy, contact angle measurement (68° ± 3° test vs. 41.6° ± 6° control), and X-ray photoelectron spectrometry measurement for fluorine atomic % (7.4% ± 0.4% test vs. not detectable control), showed that the membrane surface was modified with surface modifying macromolecule (SMM1) but maintained membrane structure and surface hydrophilicity. Zeta potential of the blood-contacting surface showed that the absolute surface charge was reduced at neutral pH (−3.3 mV ± 1.1 mV test vs. −15.6 mV ± 1.0 mV control). Platelet count reduction was significantly less for the SMM1-modified dialyzer (40.88% ± 21.89%) compared to the standard PSF dialyzer (62.62% ± 34.13%), along with Platelet Factor 4 (1824.10 ng/ml ± 436.26 ng/ml test vs. 2479.00 ng/ml ± 852.96 ng/ml control). These studies demonstrate the successful incorporation of SMM1 into the new hemodialyzer with the expected results. Our in vitro experiments indicate that the SMM1-modified hemodialyzers could improve hemocompatibility compared to standard PSF hemodialyzers and have the potential to minimize the patient's anticoagulant requirements during HD. Additional research with SMM1 additives incorporated into the entire dialysis circuit and use in a clinical settings are required to confirm these promising findings.Keywords
Funding Information
- Fresenius Medical Care North America
This publication has 38 references indexed in Scilit:
- Rationale and design of the HepZero study: a prospective, multicenter, international, open, randomized, controlled clinical study with parallel groups comparing heparin-free dialysis with heparin-coated dialysis membrane (Evodial) versus standard care: study protocol for a randomized controlled trialTrials, 2013
- Obstacles in Haemocompatibility TestingScientifica, 2013
- Surface Modification of Biomaterials: A Quest for Blood CompatibilityInternational Journal of Biomaterials, 2012
- Intrinsic clotting factors in dependency of age, sex, body mass index, and oral contraceptives: definition and risk of elevated clotting factor levelsBlood Coagulation & Fibrinolysis, 2009
- Fibrinogen adsorption and platelet lysis characterization of fluorinated surface-modified polyetherurethanesJournal of Biomedical Materials Research Part A, 2007
- Essentials of anticoagulation in hemodialysisHemodialysis International, 2007
- Clinical review: Patency of the circuit in continuous renal replacement therapyCritical Care, 2007
- Fibrinogen surface distribution correlates to platelet adhesion pattern on fluorinated surface-modified polyetherurethaneBiomaterials, 2005
- Application of macromolecular additives to reduce the hydrolytic degradation of polyurethanes by lysosomal enzymesBiomaterials, 1997
- Heparin free dialysis: Comparative data and results in high risk patientsKidney International, 1987